Regulus Therapeutics Inc. (RGLS): Price and Financial Metrics

Regulus Therapeutics Inc. (RGLS): $0.31

0.03 (+12.52%)

POWR Rating

Component Grades













Add RGLS to Watchlist
Sign Up

Industry: Biotech



in industry


  • RGLS scores best on the Value dimension, with a Value rank ahead of 62.07% of US stocks.
  • The strongest trend for RGLS is in Growth, which has been heading up over the past 49 days.
  • RGLS's current lowest rank is in the Stability metric (where it is better than 5.02% of US stocks).

RGLS Stock Summary

  • RGLS has a higher market value than just 5.14% of US stocks; more precisely, its current market capitalization is $25,417,967.
  • The volatility of Regulus Therapeutics Inc's share price is greater than that of 96.38% US stocks with at least 200 days of trading history.
  • Regulus Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -123.48%, greater than the shareholder yield of merely 3.48% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Regulus Therapeutics Inc are TARS, LOGC, SILC, CRIS, and CYTK.
  • RGLS's SEC filings can be seen here. And to visit Regulus Therapeutics Inc's official web site, go to

RGLS Valuation Summary

  • In comparison to the median Healthcare stock, RGLS's price/sales ratio is 40.09% lower, now standing at 6.8.
  • Over the past 106 months, RGLS's EV/EBIT ratio has gone up 8.9.
  • RGLS's EV/EBIT ratio has moved up 8.9 over the prior 106 months.

Below are key valuation metrics over time for RGLS.

Stock Date P/S P/B P/E EV/EBIT
RGLS 2021-08-31 6.8 1.8 -4.5 -2.5
RGLS 2021-08-30 6.6 1.8 -4.4 -2.3
RGLS 2021-08-27 6.4 1.7 -4.3 -2.2
RGLS 2021-08-26 6.0 1.6 -4.0 -1.9
RGLS 2021-08-25 6.0 1.6 -4.0 -1.9
RGLS 2021-08-24 6.1 1.7 -4.1 -2.0

RGLS Growth Metrics

    The 5 year net income to common stockholders growth rate now stands at 65.95%.
  • Its 3 year net cashflow from operations growth rate is now at 32.47%.
  • Its year over year price growth rate is now at 33.33%.
RGLS's revenue has moved up $4,928,000 over the prior 49 months.

The table below shows RGLS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 5 -13.108 -21.997
2021-06-30 10 -12.043 -14.893
2021-03-31 10 -12.245 -15.806
2020-12-31 10.006 -12.536 -15.73
2020-09-30 5.024 -20.702 -19.301
2020-06-30 0.042 -20.925 -23.2

RGLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RGLS has a Quality Grade of C, ranking ahead of 32.91% of graded US stocks.
  • RGLS's asset turnover comes in at 0.259 -- ranking 169th of 681 Pharmaceutical Products stocks.
  • XNCR, MDWD, and VRTX are the stocks whose asset turnover ratios are most correlated with RGLS.

The table below shows RGLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.259 1 -3.869
2021-03-31 0.297 1 -6.609
2020-12-31 0.309 1 -12.234
2020-09-30 0.150 1 -11.968
2020-06-30 0.001 1 -36.048
2020-03-31 0.002 1 -33.403

RGLS Price Target

For more insight on analysts targets of RGLS, see our RGLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.38 Average Broker Recommendation 1.75 (Moderate Buy)

RGLS Stock Price Chart Interactive Chart >

Price chart for RGLS

RGLS Price/Volume Stats

Current price $0.31 52-week high $1.48
Prev. close $0.28 52-week low $0.16
Day low $0.27 Volume 2,448,600
Day high $0.34 Avg. volume 1,916,005
50-day MA $0.25 Dividend yield N/A
200-day MA $0.39 Market Cap 45.25M

Regulus Therapeutics Inc. (RGLS) Company Bio

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. The company was founded in 2007 and is based in San Diego, California.

RGLS Latest News Stream

Event/Time News Detail
Loading, please wait...

RGLS Latest Social Stream

Loading social stream, please wait...

View Full RGLS Social Stream

Latest RGLS News From Around the Web

Below are the latest news stories about Regulus Therapeutics Inc that investors may wish to consider to help them evaluate RGLS as an investment opportunity.

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of enrollment in the Phase 2 HERA clinical study evaluating lademirsen (RG-012) for the treatment of adult patients with Alport Syndrome under the Company's Collaboration and License Agreement with Sanofi.

Yahoo | February 24, 2022

Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Dropped -6.08% Over A Month Are There Any Chances Of Growth?

During the last session, Regulus Therapeutics Inc. (NASDAQ:RGLS)s traded shares were 0.45 million, with the beta value of the company hitting 2.02. At the end of the trading day, the stocks price was $0.23, reflecting an intraday loss of -6.62% or -$0.02. The 52-week high for the RGLS share is $2.32, that puts it down Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Dropped -6.08% Over A Month Are There Any Chances Of Growth? Read More »

Marketing Sentinel | February 19, 2022

Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO , Feb. 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 3:00 p.m. ET . A live webcast of the presentation will be available under "Events and Presentations" through the … Full story available on

Benzinga | February 10, 2022

5 Penny Stocks Insiders Are Buying: OpGen, Regulus Therapeutics And More

The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates of 5.5%. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. OpGen The Trade: OpGen, Inc. (NASDAQ: OPGN ) Chief Operating Officer Johannes Bacher acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost $21.2...

Benzinga | January 27, 2022

Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | January 26, 2022

Read More 'RGLS' Stories Here

RGLS Price Returns

1-mo 53.85%
3-mo 37.72%
6-mo -20.00%
1-year -68.57%
3-year -74.38%
5-year -98.15%
YTD -1.59%
2021 -76.67%
2020 51.69%
2019 -4.30%
2018 -92.55%
2017 -53.78%

Continue Researching RGLS

Here are a few links from around the web to help you further your research on Regulus Therapeutics Inc's stock as an investment opportunity:

Regulus Therapeutics Inc (RGLS) Stock Price | Nasdaq
Regulus Therapeutics Inc (RGLS) Stock Quote, History and News - Yahoo Finance
Regulus Therapeutics Inc (RGLS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7655 seconds.